In conclusion, as summarized in Figure 2, S-allyl cysteine (SAC) can be proposed as a promising compound to support several physiological processes whose impairment contributes to the onset of MetS, including endothelial function, glucose and lipid metabolism, insulin responsiveness, and pancreatic β-cell health. Here, INS is linked to metabolic syndrome.